$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000112623417000041 Filed on May 05, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q4
Revenue	$10.37M	$2.761M	$12.70M
YoY Change	415.41%	-51.63%	66.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.900M	$8.200M	$7.200M
YoY Change	3.49%	-10.87%	-6.49%
% of Gross Profit
Research & Development	$18.20M	$15.73M	$20.20M
YoY Change	-33.6%	-28.32%	36.49%
% of Gross Profit
Depreciation & Amortization	$300.0K	$360.0K	$600.0K
YoY Change	-50.0%	-39.5%	20.0%
% of Gross Profit
Operating Expenses	$27.10M	$23.96M	$27.40M
YoY Change	-25.84%	-22.96%	21.78%
Operating Profit	-$16.73M	-$21.20M	-$13.97M
YoY Change	-51.56%	-16.52%	-5.77%
Interest Expense	$7.000K	$106.0K	$100.0K
YoY Change	16.67%	1414.29%
% of Operating Profit
Other Income/Expense, Net	$1.000K	-$25.00K	$100.0K
YoY Change	-98.33%	-164.1%
Pretax Income	-$16.73M	-$21.22M	-$13.80M
YoY Change	-51.47%	-16.29%	-6.76%
Income Tax	$0.00	-$310.0K	-$640.0K
% Of Pretax Income
Net Earnings	-$16.73M	-$20.91M	-$13.51M
YoY Change	-48.36%	-11.83%	-37.4%
Net Earnings / Revenue	-161.29%	-757.44%	-106.32%
Basic Earnings Per Share	-$0.57	-$0.72	-$0.46
Diluted Earnings Per Share	-$5.219M	-$6.531M	-$0.46
COMMON SHARES
Basic Shares Outstanding	29.23M shares	29.21M shares	29.13M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$107.8M	$118.2M	$131.5M
YoY Change	-32.83%	-33.6%	-33.52%
Cash & Equivalents	$107.8M	$118.2M	$131.5M
Short-Term Investments			$0.00
Other Short-Term Assets	$4.900M	$9.000M	$5.900M
YoY Change	22.5%	221.43%	18.0%
Inventory
Prepaid Expenses		$8.984M	$5.921M
Receivables
Other Receivables	$11.26M		$24.53M
Total Short-Term Assets	$130.2M	$143.2M	$167.9M
YoY Change	-24.29%	-24.43%	-19.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.886M	$6.466M	$6.835M
YoY Change	-20.83%	-38.41%	-34.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.886M	$6.466M	$6.835M
YoY Change	-20.83%	-38.41%	-34.28%
TOTAL ASSETS
Total Short-Term Assets	$130.2M	$143.2M	$167.9M
Total Long-Term Assets	$5.886M	$6.466M	$6.835M
Total Assets	$136.1M	$149.6M	$174.7M
YoY Change	-24.14%	-25.16%	-20.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.37M	$9.618M	$22.88M
YoY Change	516.87%	216.49%	525.05%
Accrued Expenses	$14.45M	$17.81M	$14.31M
YoY Change	-26.02%	60.91%	63.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	21.95%	-64.16%
Total Short-Term Liabilities	$26.30M	$27.97M	$37.91M
YoY Change	16.67%	82.76%	155.42%
LONG-TERM LIABILITIES
Long-Term Debt	$200.0K	$200.0K	$300.0K
YoY Change	-50.0%	-55.85%	-18.48%
Other Long-Term Liabilities	$7.000M	$7.100M	$7.100M
YoY Change	-2.78%	-4.05%	-6.58%
Total Long-Term Liabilities	$7.218M	$7.297M	$7.376M
YoY Change	-4.52%	-6.51%	-6.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.30M	$27.97M	$37.91M
Total Long-Term Liabilities	$7.218M	$7.297M	$7.376M
Total Liabilities	$33.52M	$35.27M	$45.28M
YoY Change	11.35%	52.61%	98.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$203.1M	-$186.4M	-$165.5M
YoY Change	48.87%	79.13%	105.98%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.098M	$1.090M	$853.0K
YoY Change	40.05%	41.37%	10.64%
Treasury Stock Shares	53.43K shares	52.24K shares	30.05K shares
Shareholders Equity	$102.6M	$114.4M	$129.5M
YoY Change
Total Liabilities & Shareholders Equity	$136.1M	$149.6M	$174.7M
YoY Change	-24.14%	-25.16%	-20.04%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q4
OPERATING ACTIVITIES
Net Income	-$16.73M	-$20.91M	-$13.51M
YoY Change	-48.36%	-11.83%	-37.4%
Depreciation, Depletion And Amortization	$300.0K	$360.0K	$600.0K
YoY Change	-50.0%	-39.5%	20.0%
Cash From Operating Activities	-$10.90M	-$13.01M	-$17.00M
YoY Change	-32.72%	-33.29%	102.38%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	$35.00K	-$100.0K
YoY Change	-94.12%	-87.54%	-80.0%
Acquisitions
YoY Change
Other Investing Activities	$200.0K	$0.00	$0.00
YoY Change	-80.0%	-100.0%	-100.0%
Cash From Investing Activities	$100.0K	-$13.00K	-$200.0K
YoY Change	-114.29%	-101.44%	-140.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$174.0K
YoY Change		-504.65%
Debt Paid & Issued, Net		$54.00K
YoY Change		-25.0%
Cash From Financing Activities	300.0K	-$228.0K	400.0K
YoY Change	-25.0%	686.21%	-93.75%
NET CHANGE
Cash From Operating Activities	-10.90M	-$13.01M	-17.00M
Cash From Investing Activities	100.0K	-$13.00K	-200.0K
Cash From Financing Activities	300.0K	-$228.0K	400.0K
Net Change In Cash	-10.50M	-$13.25M	-16.80M
YoY Change	-36.36%	-1617.75%	1020.0%
FREE CASH FLOW
Cash From Operating Activities	-$10.90M	-$13.01M	-$17.00M
Capital Expenditures	-$100.0K	$35.00K	-$100.0K
Free Cash Flow	-$10.80M	-$13.04M	-$16.90M
YoY Change	-25.52%	-34.06%	113.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29225682	shares
CY2017Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
CY2017Q1	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017Q1	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	nlnk	Genentech Upfront Payments GenentechUpfrontPayments	150000000	USD
CY2016Q1	nlnk	Merck One Time Milestones MerckOneTimeMilestones	20000000	USD
CY2014Q4	nlnk	Merck Upfront Payments MerckUpfrontPayments	30000000	USD
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	24526000	USD
CY2017Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9645000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22883000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9618000	USD
CY2016Q4	us-gaap	Accrued Fees And Other Revenue Receivable AccruedFeesAndOtherRevenueReceivable	23900000	USD
CY2017Q1	us-gaap	Accrued Fees And Other Revenue Receivable AccruedFeesAndOtherRevenueReceivable	9100000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14309000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17805000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5700000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6100000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	295535000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	301573000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4700000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5900000	USD
CY2016Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4000	USD
CY2016Q4	us-gaap	Assets Assets	174747000	USD
CY2017Q1	us-gaap	Assets Assets	149622000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	167912000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	143156000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	195620000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	176986000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131490000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118240000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18634000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-13250000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29193718	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29271898	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29163673	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29219661	shares
CY2016Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	292000	USD
CY2017Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	292000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	90000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	91000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1091000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1068000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	391000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	223000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	595000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	360000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2016Q1	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	397000	USD
CY2016Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	181000	USD
CY2017Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	18000	USD
CY2016Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	397000	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9164000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8234000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-25354000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21223000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1634000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-310000	USD
CY2016Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1021000	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	5975000	USD
CY2017Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	6287000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1501000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-9751000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2655000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-312000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	31000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	22000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-212000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-168000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1426000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-14881000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2122000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3063000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	7000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	106000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	7000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	4000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	46000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	85000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	45281000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	35268000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174747000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	149622000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37905000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	27971000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	517000	USD
CY2017Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	463000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7376000	USD
CY2017Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7297000	USD
CY2017Q1	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	843000	USD
CY2016Q1	us-gaap	Licenses Revenue LicensesRevenue	1370000	USD
CY2017Q1	us-gaap	Licenses Revenue LicensesRevenue	175000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	285000	USD
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	229000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	232000	USD
CY2017Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	234000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-29000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-228000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	902000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19507000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13009000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-23720000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-20913000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	231000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	39000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-25000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	31101000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	23959000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25393000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21198000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2900000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6100000	USD
CY2016Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	6000000	USD
CY2017Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	6000000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	397000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2016Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2017Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	4000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	237000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	281000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5921000	USD
CY2017Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8984000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	63000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	1183000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	22000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-23720000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-20913000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6835000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6466000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	72000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	54000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21937000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15725000	USD
CY2016	us-gaap	Restructuring Charges RestructuringCharges	11600000	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165508000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186421000	USD
CY2016Q1	us-gaap	Revenue From Grants RevenueFromGrants	4338000	USD
CY2017Q1	us-gaap	Revenue From Grants RevenueFromGrants	2586000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	5708000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	2761000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4716000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5975000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	78179	shares
CY2017Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5975000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	63000	USD
CY2017Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	22191	shares
CY2017Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	237000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	129466000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	114354000	USD
CY2016	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	4000000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	30045	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	52237	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	853000	USD
CY2017Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1090000	USD
CY2016Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4300000	USD
CY2017Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	7500000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28856944	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29213488	shares
CY2017Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$20.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from an at the market (ATM) offering completed in 2015. In connection with two license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. The Company's cash and cash equivalents after these agreements and offerings are expected to be adequate to satisfy the Company's liquidity requirements through 2018. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-17-000041-index-headers.html	Edgar Link	pending
0001126234-17-000041-index.html	Edgar Link	pending
0001126234-17-000041.txt	Edgar Link	pending
0001126234-17-000041-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
idopipelinechart170427.jpg	Edgar Link	pending
newlinklogorgbwtaga01a01a07.jpg	Edgar Link	pending
nlnk-20170331.xml	Edgar Link	completed
nlnk-20170331.xsd	Edgar Link	pending
nlnk-20170331x10q.htm	Edgar Link	pending
nlnk-20170331xex311.htm	Edgar Link	pending
nlnk-20170331xex312.htm	Edgar Link	pending
nlnk-20170331xex321.htm	Edgar Link	pending
nlnk-20170331_cal.xml	Edgar Link	unprocessable
nlnk-20170331_def.xml	Edgar Link	unprocessable
nlnk-20170331_lab.xml	Edgar Link	unprocessable
nlnk-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2017 Q2 Form 10-Q Financial Statement

#000112623417000041 Filed on May 05, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2017 Q2 Form 10-Q Financial Statement

#000112623417000041 Filed on May 05, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo